The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy Martina AhlmannGeorg Hempel Review Article 19 September 2016 Pages: 661 - 671
Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting? James C. SorensenBeatrice D. CheregiEmma Rybalka Review Article 11 May 2016 Pages: 673 - 683
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers Ji Hyun ParkMyung Joo KangSung-Bae Kim Original Article 04 August 2016 Pages: 685 - 695
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin Kenneth T. LuuJoseph Boni Original Article 04 August 2016 Pages: 697 - 708
Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice Siok Yean TanMei Mei WongIgnacio Segarra Original Article 05 August 2016 Pages: 709 - 718
Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial Ken-ichi OkadaManabu KawaiHiroki Yamaue Original Article 08 August 2016 Pages: 719 - 726
Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors Ding WangFadi BraitehPatricia LoRusso Original Article 09 August 2016 Pages: 727 - 733
Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein Jae Guen SongYeo Song LeeHyo-Kyung Han Original Article 12 August 2016 Pages: 735 - 744
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer Seiko BunMayu YunokawaKenji Tamura Original Article 13 August 2016 Pages: 745 - 752
Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage Prabakaran D. SubramanianZhengzhe AnWoo-Yoon Park Original Article 17 August 2016 Pages: 753 - 762
Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients Vikram GotaGirish ChinnaswamyPurna Kurkure Original Article 19 August 2016 Pages: 763 - 768
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102 Toshio KuboKeiichi FujiwaraKatsuyuki Kiura Original Article 20 August 2016 Pages: 769 - 774
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies Helen SwaislandRuth PlummerAnitra Fielding Original Article 23 August 2016 Pages: 775 - 784
Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1 Shin NishioRyo KitagawaToshiharu Kamura Original Article 23 August 2016 Pages: 785 - 790
Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization Dengke BaoYanna BaJinliang Xing Original Article 24 August 2016 Pages: 791 - 799
The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma Jiangzheng ZengLiangxia YangXinbao Hao Original Article 25 August 2016 Pages: 801 - 808
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer Takeshi KawakamiNozomu MachidaYusuke Onozawa Original Article 26 August 2016 Pages: 809 - 814
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer Muhammad Wasif SaifJames A. KnostBert H. O’Neil Original Article 26 August 2016 Pages: 815 - 824
Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma Dong-Yeop ShinByung Hyun ByunSang Moo Lim Original Article 30 August 2016 Pages: 825 - 831
Impact of metronomic neoadjuvant chemotherapy on early tongue cancer Shinichiro KinaToshiyuki NakasoneAkira Arasaki Original Article 30 August 2016 Pages: 833 - 840
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer Kyong Joo LeeSeung Woo YiSeung Woo Park Original Article 01 September 2016 Pages: 841 - 846
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis Kevin J. FreiseMartin DunbarAhmed Hamed Salem Original Article 01 September 2016 Pages: 847 - 853
Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma Hiroshi KatoNaoto SassaKiyofumi Yamada Original Article 01 September 2016 Pages: 855 - 862
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague–Dawley rats Richard A. ForsgårdRiitta KorpelaPia Österlund Original Article Open access 02 September 2016 Pages: 863 - 874
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines Didier MeulendijksLinda M. HenricksJan H. M. Schellens Short Communication 20 August 2016 Pages: 875 - 880
